McN-5558 is a drug which acts as a selective noradrenaline reuptake inhibitor. It was investigated for potential application as an antidepressant, but was never developed for clinical use.[1][2]

McN-5558
Identifiers
  • (6S,10bR)-6-[3-(trifluoromethyl)phenyl]-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H18F3N
Molar mass317.355 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2C3=CC=CC=C3[C@@H](CN2C1)C4=CC(=CC=C4)C(F)(F)F
  • InChI=1S/C19H18F3N/c20-19(21,22)14-6-3-5-13(11-14)17-12-23-10-4-9-18(23)16-8-2-1-7-15(16)17/h1-3,5-8,11,17-18H,4,9-10,12H2/t17-,18+/m0/s1
  • Key:LWXKKDYZAXBAPH-ZWKOTPCHSA-N

Pharmacology

edit

McN-5558 is described as a serotonin–norepinephrine reuptake inhibitor (SNRI) with equilibrium constants (Kis) for various neurotransmitter transporters:[2]

Compound 37b norepinephrine transporter
(NE)
dopamine transporter
(DAT)
serotonin transporter
(SERT)
racemic 1.0 54.3 23.0
(+) 1.5 25.7 9.1
(-) 2570 7690 2920

These data show that virtually all of the binding affinities resides in a single enantiomer. Consequently, the compound displays a very high eudysmic ratio.

In terms of the SAR, the meta-trifluorophenyl group was seen for fenfluramine, Benfluorex, and Ethyltrifluoromethylaminoindane.[3][4][5] These are anorexigenic agents for the treatment of obesity and eating disorders.

See also

edit

References

edit
  1. Maryanoff BE, McComsey DF, Gardocki JF, Shank RP, Costanzo MJ, Nortey SO, et al. (August 1987). "Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships". Journal of Medicinal Chemistry. 30 (8): 1433–1454. doi:10.1021/jm00391a028. PMID 3039136.
  2. 1 2 Frazee WJ, Ohnmacht CJ, Malick JB (1985). Chapter 4. Antidepressants. Annual Reports in Medicinal Chemistry. Vol. 20. Elsevier. pp. 31–40. doi:10.1016/S0065-7743(08)61030-1. ISBN 978-0-12-040520-6.
  3. Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, Nichols DE (March 1998). "Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential". Pharmacology, Biochemistry, and Behavior. 59 (3): 709–715. doi:10.1016/s0091-3057(97)00557-1. PMID 9512076.
  4. "2-[1-Methyl-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]propan-2-ol". PubChem. U.S. National Library of Medicine. CID 13363402.
  5. US 4485109, Ciganek E, "4-Aryl-4-piperidinecarbinols", issued 27 November 1984, assigned to Bristol Myers Squibb Pharma Co.